grant
Center for Cancer Systems Therapeutics (CaST)
Organization COLUMBIA UNIVERSITY HEALTH SCIENCESLocation NEW YORK, UNITED STATESPosted 19 Sept 2023Deadline 31 Aug 2028
NIHUS FederalResearch GrantFY20253-D structure3-dimensional structure3D structureAccelerationAddressAdvanced CancerAdvanced Malignant NeoplasmBehaviorBindingBiologicalBiological MarkersBody TissuesBrain MetastasisBuffersCancer CenterCancer TreatmentCancersCell BodyCell Communication and SignalingCell SignalingCellsClinicalCollaborationsCombined Modality TherapyDNA mutationDependenceDevelopmentDisease-Free SurvivalDissectionDrug TherapyDrug resistanceDrugsEducationEducational aspectsEndocrineEpigeneticEpigenetic ChangeEpigenetic MechanismEpigenetic ProcessEventEvent-Free SurvivalFosteringGene TranscriptionGeneticGenetic ChangeGenetic TranscriptionGenetic defectGenetic mutationGoalsImmune mediated therapyImmunologically Directed TherapyImmunosuppressionImmunosuppression EffectImmunosuppressive EffectImmunotherapyIndividualIntervention TrialInterventional trialIntracellular Communication and SignalingIntratumoral heterogeneityInvestigatorsLigandsMaintenanceMalignantMalignant - descriptorMalignant CellMalignant MelanomaMalignant Neoplasm TherapyMalignant Neoplasm TreatmentMalignant NeoplasmsMalignant TumorMediatingMedicationMelanomaMetastatic Neoplasm to the BrainMetastatic Tumor to the BrainMetastatic malignant neoplasm to brainMethodologyMolecularMolecular InteractionMultimodal TherapyMultimodal TreatmentMutationNSCLCNSCLC - Non-Small Cell Lung CancerNetwork-basedNon-MalignantNon-Small Cell Lung CancerNon-Small-Cell Lung CarcinomaOutcomePatientsPharmaceutical PreparationsPharmacological TreatmentPharmacologyPharmacotherapyPhenotypeProductivityPrognosisProteomeProteomicsRNA ExpressionReceptor ProteinResearchResearch PersonnelResearchersReverse engineeringScienceScientistSignal TransductionSignal Transduction SystemsSignalingStructureSystemSystems BiologySystems IntegrationTechnologyTherapeuticTherapy trialTissuesTranscriptionValidationactionable mutationactionable variantsanti-cancer therapybio-markersbiologicbiologic markerbiological signal transductionbiomarkerbrain micrometastasiscancer cellcancer microenvironmentcancer progressioncancer therapycancer-directed therapycell typecheck point blockadecheckpoint blockadeclinical relevanceclinical translationclinically relevantclinically translatablecombination therapycombined modality treatmentcombined treatmentdesigndesigningdevelopmentaldrug interventiondrug mechanismdrug resistantdrug treatmentdrug/agentepigeneticallyevidence baseforginggenome mutationheterogeneity in tumorsimmune check point blockadeimmune checkpoint blockadeimmune microenvironmentimmune suppressionimmune suppressive activityimmune suppressive functionimmune therapeutic approachimmune therapeutic interventionsimmune therapeutic regimensimmune therapeutic strategyimmune therapyimmune-based therapiesimmune-based treatmentsimmuno therapyimmunosuppressive activityimmunosuppressive functionimmunosuppressive microenvironmentimmunosuppressive responseimmunosuppressive tumor microenvironmentimprovedinnovateinnovationinnovativeintegrated systeminterestintra-tumoral heterogeneityintratumor heterogeneitymalignancymulti-modal therapymulti-modal treatmentmultiomicsmultiple data sourcesmultiple omicsneoplasm progressionneoplasm/cancerneoplastic progressionnext generationnonmalignantnoveloutreachpanomicsparacrinepatient responsibilitiespharmaceutical interventionpharmacologicpharmacological interventionpharmacological therapypharmacology interventionpharmacology treatmentpharmacotherapeuticsprogramsreceptorreceptor-mediated signalingrecruitrelapse patientsresistance to Drugresistant to Drugsingle cell technologysystem integrationtargeted drug therapytargeted drug treatmentstargeted therapeutictargeted therapeutic agentstargeted therapytargeted treatmentthree dimensional structuretumortumor heterogeneitytumor immune microenvironmenttumor initiationtumor microenvironmenttumor progressiontumor-immune system interactionsvalidationsvirtual
Description preview
Patients with aggressive cancers often present with no pharmacologically actionable mutations and poor or no sensitivity to immune checkpoint blockade, thus deriving only modest improvement in disease-free survival from targeted therapy and immunotherapy. Tumor heterogeneity adds further complexity by fostering reprogramming, adaptation,…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click